1. The 4-hydroxylation of debrisoquine was measured in 42 patients with chronic discoid psoriasis. 2. The proportion of poor metabolisers (4.8%) and the median metabolic ratio (0.5) in psoriatics were similar to that reported previously in a healthy British population. 3. We conclude that the abnormality of microsomal mono-oxygenase activity which we have found in the skin and other tissues of psoriatics is not due to a generalised (non-specific) impairment of microsomal oxidation and may be enzyme specific.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Alvares AP, Kappas A, Levin W, Conney AH (1973) Inducibility of benz(α)pyrene hydroxylase in human skin by polycyclic hydrocarbons. Clin Pharmacol Ther 14: 30–40
Chapman PH, Rawlins MD, Shuster S (1979) The activity of aryl hydrocarbon hydroxylase in adult human skin. Br J Clin Pharmacol: 499–503
Chapman PH, Rawlins MD, Shuster S (1979) The activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet 1: 297–298
Chapman PH, Rawlins MD, Shuster S, Rogers S (1979) Impaired epidermal microsomal AHH activity in discoid and pustular psoriasis. J Invest Dermatol 72: 267–268
Shuster S, Rawlins MD, Chapman PH, Rogers S (1980) Decreased epidermal AHH and localised pustular psoriasis. Br J Dermatol 103: 23–26
Chapman PH, Kersey PJ, Keys B, Shuster S, Rawlins MD (1980) Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J 281: 1315–1315
Chapman PH, Moss C, Keys B, Shuster S, Rawlins MD (1981) Antipyrine clearance in psoriasis. Br Med J 282: 20–21
Idle PJ, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL (1979) The metabolism of14C-debrisoquine in man. Br J Clin Pharmacol 7: 257–266
Danhof M, Breimer DD (1979) Studies on the different metabolic pathways of antipyrine in man. 1. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol 8: 529–537
Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M (1979) Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1: 455–458
Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in the British white population. J Med Genet 17: 102–105
Mahgoub A, Idle JR, Dring LG. Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586
Shuster S, Chapman PH, Rawlins MD (1979) Psoriasis and Cancer. Br Med J 1: 941–942
About this article
Cite this article
Chapman, P.H., Rawlins, M.D., Shuster, S. et al. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis. Eur J Clin Pharmacol 21, 257–258 (1981). https://doi.org/10.1007/BF00627929
- chronic discoid psoriasis
- microsomal oxidation